Docetaxel treatment in the elderly patient with hormone refractory prostate cancer.

Research output: Contribution to journalArticle

Abstract

Docetaxel is an anti-microtubular agent in the family of the taxanes, now FDA approved as first line chemotherapy for the treatment of hormone refractory metastatic prostate cancer. Recent data from two large randomized Phase III trials showed a survival advantage in hormone refractory prostate cancer patients treated with docetaxel. This discovery changed the perceptions about utilization of chemotherapy for this devastating disease and introduced a new paradigm/standard of care treatment for this patient population. The management of elderly patients with metastatic prostate cancer is an important issue because according to data from the Surveillance, Epidemiology, and End Results (SEER) program, the American Cancer Society, and the United Nations, the incidence of prostate cancer in elderly men is expected to increase since people are living longer. In this paper we will review the results of trials evaluating docetaxel in hormone refractory prostate cancer and the implications of these trials as they relate to diagnosis and management of this disease in the elderly man.

Original languageEnglish (US)
Pages (from-to)555-560
Number of pages6
JournalClinical Interventions in Aging
Volume2
Issue number4
StatePublished - 2007

Fingerprint

docetaxel
Prostatic Neoplasms
Hormones
SEER Program
Therapeutics
Drug Therapy
Taxoids
United Nations
Standard of Care
Disease Management
Survival
Incidence

ASJC Scopus subject areas

  • Geriatrics and Gerontology

Cite this

Docetaxel treatment in the elderly patient with hormone refractory prostate cancer. / Sinibaldi, Victoria.

In: Clinical Interventions in Aging, Vol. 2, No. 4, 2007, p. 555-560.

Research output: Contribution to journalArticle

@article{fbc3a16c023743ccaa09477696d5eddf,
title = "Docetaxel treatment in the elderly patient with hormone refractory prostate cancer.",
abstract = "Docetaxel is an anti-microtubular agent in the family of the taxanes, now FDA approved as first line chemotherapy for the treatment of hormone refractory metastatic prostate cancer. Recent data from two large randomized Phase III trials showed a survival advantage in hormone refractory prostate cancer patients treated with docetaxel. This discovery changed the perceptions about utilization of chemotherapy for this devastating disease and introduced a new paradigm/standard of care treatment for this patient population. The management of elderly patients with metastatic prostate cancer is an important issue because according to data from the Surveillance, Epidemiology, and End Results (SEER) program, the American Cancer Society, and the United Nations, the incidence of prostate cancer in elderly men is expected to increase since people are living longer. In this paper we will review the results of trials evaluating docetaxel in hormone refractory prostate cancer and the implications of these trials as they relate to diagnosis and management of this disease in the elderly man.",
author = "Victoria Sinibaldi",
year = "2007",
language = "English (US)",
volume = "2",
pages = "555--560",
journal = "Clinical Interventions in Aging",
issn = "1176-9092",
publisher = "Dove Medical Press Ltd.",
number = "4",

}

TY - JOUR

T1 - Docetaxel treatment in the elderly patient with hormone refractory prostate cancer.

AU - Sinibaldi, Victoria

PY - 2007

Y1 - 2007

N2 - Docetaxel is an anti-microtubular agent in the family of the taxanes, now FDA approved as first line chemotherapy for the treatment of hormone refractory metastatic prostate cancer. Recent data from two large randomized Phase III trials showed a survival advantage in hormone refractory prostate cancer patients treated with docetaxel. This discovery changed the perceptions about utilization of chemotherapy for this devastating disease and introduced a new paradigm/standard of care treatment for this patient population. The management of elderly patients with metastatic prostate cancer is an important issue because according to data from the Surveillance, Epidemiology, and End Results (SEER) program, the American Cancer Society, and the United Nations, the incidence of prostate cancer in elderly men is expected to increase since people are living longer. In this paper we will review the results of trials evaluating docetaxel in hormone refractory prostate cancer and the implications of these trials as they relate to diagnosis and management of this disease in the elderly man.

AB - Docetaxel is an anti-microtubular agent in the family of the taxanes, now FDA approved as first line chemotherapy for the treatment of hormone refractory metastatic prostate cancer. Recent data from two large randomized Phase III trials showed a survival advantage in hormone refractory prostate cancer patients treated with docetaxel. This discovery changed the perceptions about utilization of chemotherapy for this devastating disease and introduced a new paradigm/standard of care treatment for this patient population. The management of elderly patients with metastatic prostate cancer is an important issue because according to data from the Surveillance, Epidemiology, and End Results (SEER) program, the American Cancer Society, and the United Nations, the incidence of prostate cancer in elderly men is expected to increase since people are living longer. In this paper we will review the results of trials evaluating docetaxel in hormone refractory prostate cancer and the implications of these trials as they relate to diagnosis and management of this disease in the elderly man.

UR - http://www.scopus.com/inward/record.url?scp=39749173931&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=39749173931&partnerID=8YFLogxK

M3 - Article

C2 - 18225455

AN - SCOPUS:39749173931

VL - 2

SP - 555

EP - 560

JO - Clinical Interventions in Aging

JF - Clinical Interventions in Aging

SN - 1176-9092

IS - 4

ER -